Canaccord lowered the firm’s price target on Insulet to $175 from $355 and keeps a Buy rating on the shares. The firm said they delivered impressive results in Q3, beating revenue estimates and raising FY/23 US revenue guidance, with upside driven by continued strength across the business with strong new patient starts both US and globally but the target was lowered due to lower comps.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PODD: